ETAGEN PHARMA

ETAGEN Pharma was founded in 2014 by Tod Woolf, Ph.D. and Richard Hogrefe, PhD. ETAGEN's technology treats disease by selectively editing out mutated sequences or editing in protective genomic variants. ETAGEN offers field-specific licenses to its foundational editing platform IP for BASE Editing, PRIME editing, oligo-only editing and for use as enhanced donor DNA in combination with programmable nuclease-mediated editing... ETAGEN's Therapeutic Editing™ oligomers specifically bind to and permanently correct disease-causing mutations. ETAGEN employs proprietary chemically-modified nucleic acid oligomers (ETAMERS™) that act as both the guide and template for triggering precise editing by the endogenous DNA repair machinery, addressing the need for a more simple and specific editing platform for in vivo therapeutic applications. ETAMERS create precise repairs without causing undesired insertions and deletions. ETAMERS are also employed as an improved donor DNA for use with programmable..